Charpin C, Dicaire M J, Barbeau B, Lavaut M N, Andonian C, Devictor B, Allasia C, Bonnier P, Mandeville R
Centre Hospitalo-Universitaire Timone, Marseille, France.
Med Oncol Tumor Pharmacother. 1991;8(4):243-51. doi: 10.1007/BF02987193.
MoAbF9 immunoreactivity was investigated in frozen sections of 123 breast carcinomas using an avidin or streptavidin biotin peroxidase kit. A standardized computer image analysis system was used to evaluate immunostaining. The percent of cell surface staining and mean optical densities were correlated with morphological criteria of prognosis such as tumor size histological grade, blood and lymph invasion and axillary lymph node involvement, with immunoreactivity to other MoAb, i.e. Ki67, anti-RE and anti-RP, anti-p.HER-2/neu and with tumor aneuploidy and AgNORs content in tumor cell nuclei. Despite some heterogeneity, MoAbF9 was reactive with all breast carcinomas tested. The percent of F9 immunostained cell surface and mean optical density increased with Ki67 immunoreactivity, tumor aneuploidy and AgNORs nucleus surface but were independent of p.HER-2/neu oncoprotein distribution and tumor receptor content. These findings suggest that F9 could not only allow detection axillary lymph node micrometastases but also be used as plasmatic marker for tumor recurrence and metastases.
使用抗生物素蛋白或链霉抗生物素蛋白生物素过氧化物酶试剂盒，在123例乳腺癌的冰冻切片中研究了单克隆抗体F9的免疫反应性。采用标准化的计算机图像分析系统评估免疫染色。细胞表面染色百分比和平均光密度与肿瘤大小、组织学分级、血液和淋巴浸润以及腋窝淋巴结受累等预后形态学标准相关，与其他单克隆抗体（即Ki67、抗RE和抗RP、抗p.HER-2/neu）的免疫反应性相关，还与肿瘤细胞非整倍体及肿瘤细胞核中银染核仁组织区（AgNORs）含量相关。尽管存在一些异质性，但单克隆抗体F9与所有检测的乳腺癌均有反应。F9免疫染色的细胞表面百分比和平均光密度随Ki67免疫反应性、肿瘤非整倍体和AgNORs核表面增加，但与p.HER-2/neu癌蛋白分布和肿瘤受体含量无关。这些发现表明，F9不仅可以用于检测腋窝淋巴结微转移，还可以用作肿瘤复发和转移的血浆标志物。
